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Abstract
Background: Measurement of liver stage development is of key interest in malaria biology and vaccine studies.
Parasite development in liver cells can be visualized in real-time, both in culture and in live mice, using a
transgenic Plasmodium berghei parasite, PbGFP-Luccon, expressing the bioluminescent reporter luciferase. This study
explores the benefit of using these parasites for the evaluation of immunity against malaria, compared to qRT-PCR
techniques in vivo and in vitro.
Methods: Mice were immunized with either radiation attenuated sporozoites (RAS) or wildtype sporozoites under
chloroquine prophylaxis (CPS) and challenged with PbGFP-Luccon. The in vitro transgenic sporozoites neutralization
assay (TSNA) was adapted by replacing PbCS(Pf) parasites for PbGFP-Luccon parasites.
Results: Application of PbGFP-Luccon transgenic parasites provides live quantitative visual information about the relation
between parasite liver load and protection. Moreover, fast and reproducible results are obtained by using these parasites
in the transgenic sporozoites neutralization assay, measuring functional antibody-mediated immune responses.
Conclusions: PbGFP-Luccon parasites are a straightforward and valuable tool for comprehension of the biological
and immunological principles underlying protection against malaria.
Background
Transgenic organisms that express a bioluminescent
reporter are increasingly used due to easy handling and
visualization. Plasmodium berghei parasites, expressing
the bioluminescent reporter luciferase (PbGFP-Luccon)
have been used to visualize and quantify parasite devel-
opment in vitro in hepatic cells and in vivo in mice
using real-time luminescence imaging [1].
Measurement of liver stage development is of key inter-
est in malaria biology and vaccine studies. Protection
against the liver stage is one of the targets to abrogate
the infection. Quantification of the number of parasites
in hepatocytes is an important read-out to determine
inhibitory activity. This quantification of in vitro [2] and
in vivo [3] parasite liver load is usually performed by
(qRT)-PCR. This technique, however, is time-consuming
and costly, since mice need to be sacrificed at each time
point for in vitro quantification.
The use of in vivo and in vitro imaging of luciferase
expressing parasites has some requisites. First, it requires
that the luciferase expressing parasites are qualitative and
quantitative biologically comparable to wildtype in terms
of liver and blood infectivity. Second, the in vivo and in
vitro parasite quantification by measurement of lumines-
cence signaling needs to correlate to the established qRT-
PCR methods. Previously we showed that the P. berghei
line 676m1cl1 line (PbGFP-Luccon) and wildtype (WT)
sporozoites have identical motility, cell traversal and in
vitro and in vivo hepatocyte infectivity. Moreover, detailed
examination revealed that luciferase expression correlated
tightly with parasite 18S rRNA levels measured by qRT-
PCR [1]. Therefore, this transgenic parasite seems suitable
for a quantitative analysis of parasite load.
This study aimed to explore the use of PbGFP-Luccon
parasites in both in vivo and in vitro studies evaluating
immunity against malaria. For the in vivo studies, mice
were immunized with either radiation attenuated sporo-
zoites (RAS) or wildtype sporozoites under chloroquine
prophylaxis (CPS) and subsequently challenged with
PbGFP-Luccon. For the in vitro studies, the transgenic
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by replacing PbCS(Pf) parasites for PbGFP-Luccon
parasites [2].
Methods
Mice
Female C57BL6/J mice, eight weeks of age, were pur-
chased from Elevage Janvier (France). All studies have
been performed according to the regulations of the Dutch
“Animal On Experimentation act” and the European
guidelines 86/609/EEG. Approval was obtained from the
Radboud University Experimental Animal Ethical Com-
mittee (RUDEC 2009-019).
Mosquito infection and preparation of sporozoites
The previously described, transgenic P. berghei line
676m1cl1 line (PbGFP-Luccon) [1] and its reference clone
of ANKA strain cl15cy1, were used in this study.
Anopheles stephensi mosquitoes were infected by feeding
on infected mice using standard methods of mosquito
infection [4]. On day 21 after infection, the salivary glands
of the mosquitoes were collected by hand-dissection. Sali-
vary glands were collected in DMEM (Dulbecco’sM o d i -
fied Eagle Medium from GIBCO) and homogenized in a
homemade glass grinder. The free sporozoites were
counted in a Bürker-Türk counting chamber using phase-
contrast microscopy.
Immunization of mice with radiation attenuated
sporozoites (RAS) or sporozoites under chloroquine
prophylaxis (CPS)
C57BL/6 mice were immunized with wildtype P. berghei
radiation attenuated sporozoites (RAS) or sporozoites
under chloroquine prophylaxis (CPS). Immunizations
were performed by i.v injection with three doses of 1 ×
10
4 (RAS and CPS) or 4 × 10
3 (CPS) sporozoites, with a
7 day interval between the boosts. For CPS immuniza-
tion, mice received 800 μg chloroquine base (cq-dipho-
sphate Sigma) in PBS i.p, starting from sporozoite
injection up to two weeks after the last immunization.
Absence of blood stage parasites was confirmed by
examination of Giemsa-stained blood smears of tail
blood at the end of the chloroquine treatment period
and approximately 1 day before challenge. Mice were
challenged two weeks after ending choroquine treat-
ment. Irradiation of sporozoites was performed by expo-
sure of infected A. stephensi mosquitoes to 16,000 rad
of g-radiation (Cesium-137 Gammacel 1000).
Challenge and real time in vivo imaging of liver stage
development in RAS and CPS immunized mice
Immunized and control C57BL/6 mice were challenged
by the bite of 5-11 infectious mosquitoes or by intrave-
nous injection of 1 × 10
4 PbGFP-Luccon sporozoites in
the tail (200 ul). Control mice consisted of two groups,
group 1 received chloroquine similar to the CPS immu-
nized mice and group 2 did not receive chloroquine.
Giemsa stained bloodsmears were prepared every other
day starting from day 3 to day 21 after challenge, to
monitor for blood stage parasitaemia. Parasite liver load
in animals was visualized through imaging of whole
bodies using the in vivo imaging system Lumina (Caliper
Life Sciences, USA) as described [1], with some small
adaptations. Briefly, animals were anesthetized using the
isofluorane-anesthesia system, their belly was shaved
and D-luciferin dissolved in PBS (100 mg/kg; Caliper
Life Science, Belgium) was injected subcutaneously (in
the neck). Animals were kept anesthetized during the
measurements, performed within 3-5 minutes after the
injection of D-luciferin. Bioluminescence imaging was
performed with a 10 cm field of view, medium binning
factor and an exposure time of 300 seconds. Biolumines-
cent intensities were expressed in total flux of photons.
Real time transgenic PbGFP-Luccon sporozoites
neutralization assay
The TSNA (transgenic sporozoites neutralization assay)
protocol was adapted from Kumar et al. (Figure 1). Plasma
was obtained from immunized (three doses of 1 × 10
4 ;
RAS and CPS) and naive C57BL/6 mice, 21 days post chal-
lenge by mosquito bite; blood was collected by heart punc-
ture after i.v. injection of 50 i.u. of heparin. Blood samples
were centrifuged at 2000 rpm for 5 minutes (RT), plasma
was collected and transferred to cryotubes (Nunc) and
stored at -80°C for later use. Prior to the TSNA assay,
plasma samples were thawed and centrifuged at 13,000
rpm for one minute (RT) to remove protein aggregates.
PbGFP-Luccon sporozoites were pre-incubated for 30 min-
utes on ice with plasma of naive or immunized mice (1:1
ratio).
Pre-incubated sporozoites were added to wells contain-
ing monolayers of 1 × 10
5 pre-seeded Huh-7 hepatocyte
cultures (1 ml/well in 24 well plates). Huh-7 cells (human
liver hepatoma cells) were preferred over standard HepG2
cells [2] since in these cells, luciferase expression corre-
lated slightly better with parasite 18S rRNA levels mea-
sured by qRT-PCR [1]. Huh-7 were suspended in 1 ml of
‘complete’ DMEM (DMEM, Gibco, supplemented with
10% FCS, 1% penicillin/streptomycin and 1% Glutamax)
the day prior to infection, seeded in 24 well plates (10
5
cells/well) and incubated overnight. For each plasma sam-
ple, 3 × 10
4 sporozoites each were added to duplicate
wells and plates were centrifuged 10 minutes at 1800 × g
(Eppendorf centrifuge 5810 R). 40 hours after sporozoite
addition, cells were washed once with PBS and lysed in
200 μlo fc e l lc u l t u r el y s i sr eagent obtained from the
Promega Luciferase Assay System Kit
® (Promega, PT).
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intensity with the Lumina system. The in vivo imaging sys-
tem Lumina (Caliper Life Sciences, USA) was used to
measure luciferase activity of infected Huh-7 cells. Quanti-
tative analysis was performed by measuring the lumines-
cence signal intensity per well using the ROI settings of
the Living Image
® 3.0 software. ROI measurements are
expressed in total flux of photons. 70 μl of Luciferase
Assay Substrate (Promega Luciferase Assay System Kit
®)
was added to 20 μl of lysed hepatocyte cultures in a white
96-well plate (Dynex Technologies, USA). Biolumines-
cence images were acquired with a 7 cm FOV, medium
binning factor and an exposure time of 10-30 seconds.
Percent inhibition was calculated by the following formula;
1 - (average bioluminescence in immune plasma cultures/
average bioluminescence in naive plasma cultures) ×
100%.
Results
Challenge of immunized mice with PbGFP-Luccon
sporozoites
Mice immunized with CPS or RAS as well as control mice
were challenged by PbGFP-Luccon infected mosquitoes and
protection against malaria was evaluated by blood smear
reading and real time in vivo imaging. All control
challenged mice (n = 10) developed asexual parasitaemia
and a positive bioluminescent liver signal by real-time in
vivo imaging at 44 hours post challenge (Figure 2a). All
mice immunized by CPS (n = 10) or RAS (n = 10) with a
dose regimen of three times 10
4 sporozoites and challenged
by infectious mosquito bites, neither became parasitaemic
nor displayed any bioluminescent signal originating from
the liver (Figure 2a). Next, the robustness of protective
immunity was explored by increasing the challenge level in
mice that were immunized with CPS by a lower dose regi-
men of three times 4 × 10
3 sporozoites. Mice were chal-
lenged by i.v injection of 1 × 10
4 PbGFP-Luccon
sporozoites and all immunized mice remained negative.
These results are in line with the data obtained by in vivo
imaging; mice immunized with CPS showed no biolumi-
nescent signal, in contrast to control mice, with positive
images at 30 to 45 hours post challenge (Figure 2b). There-
fore, the use of PbGFP-Luccon in a challenge model, com-
bined with bioluminescent imaging permits determination
of protective efficacy in the liver post-immunization.
Real time transgenic PbGFP-Luccon sporozoites
neutralization assay
To evaluate the potential benefits of PbGFP-Luccon for
assessment of protection in vitro, we adapted the
Real time transgenic sporozoite neutralization assay
Schematic representation
HUHͲ7hepatocytes(100.000cells/well)
Incubationfor24
hoursat37 C
Lysisofhepatocytes
WtGFPlucsporozoites(30.000spz/well)
PreͲincubationofsporozoiteswithplasma
(inglasstubes,for30minutesonice)
AdditionofpreͲincubated
sporozoitestohepatocytes
Plasmaofnaiveorimmunizedmice
Incubationfor40
hoursat37 C
Detectionofluciferase
activitywithIVIS
Figure 1 Schematic representation of the adapted transgenic PbGFP-Luccon sporozoite neutralization assay. Neutralization of hepatocyte
invasion by transgenic sporozoites was performed by incubation of naive or immune plasma obtained from (non-) immunized mice with the
transgenic sporozoites. Neutralization was performed for 30 minutes on ice before the antibody/sporozoites mix was added to Huh-7 cells
containing wells and incubated for 40 h at 37°C. This figure is adapted from figure 1 described by Kumar et al. [2]
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Figure 2 Real-time in vivo parasite liver load upon challenge in mice immunized with CPS or RAS. (A) Image (2 representative mice for
each group) of the parasite liver load in control (n = 10), CPS (n = 10) and RAS immunized (n = 10) C57BL/6 mice 44 hours post challenge.
Mice were immunized i.v with 1 × 10
4 sporozoites followed by two boosts of 1 × 10
4 sporozoites. Challenge was performed by infectious
mosquito bites. The rainbow image visible in the naive mice represents the total flux of photons (p/sec/cm
2) in that area. (B) Image (2 control
mice and 3 immunized mice) of the parasite liver load in control (n = 3) and CPS immunized (n = 5) C57BL/6 mice 30-45 hours post challenge.
Mice were immunized with 4 × 10
3 sporozoites by i.v injection followed by two boosts of 4 × 10
3 sporozoites. Challenge was performed by
injection of 1 × 10
4 PbGFP-Luccon sporozoites i.v. The rainbow image visible in the control mice represents the total flux of photons (p/sec/cm
2)
in that area.
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as performed by Kumar et al. [2] by replacing the PbCS
(Pf) sporozoites with PbGFP-Luccon sporozoites. The use
of bioluminescent parasites in the TSNA has some
requisites. Recently, Ploemen et al. described the highly
significant quantitative correlation between parasite 18S
rRNA levels measured by qRT-PCR and luminescence
intensity for different numbers of PbGFP-Luccon sporo-
zoites invaded into Huh-7 hepatocytes (Spearman rho =
0.83) [1]. As a follow-up of these results, a dose titration
with 10 - 50.000 PbGFP-Luccon sporozoites, added to a
Huh-7 hepatocyte culture was performed and biolumi-
nescent intensity was measured 40 hrs post invasion
(Figure 3a). Luminescent intensities increased linear
(R
2 = 0.97) with the number of PbGFP-Luccon sporo-
zoites added to a Huh-7 hepatocyte culture. These para-
sites, therefore, may be used in an adapted TSNA.
Plasma from protected C57BL/6 mice was used in the
adapted TSNA, after CPS or RAS immunization. Invasion
of Huh-7 cells by PbGFP-Luccon sporozoites pre-incubated
with plasma of protected mice was significantly inhibited
compared to invasion by sporozoites pre-incubated with
plasma of naive mice (p < 0.05) (Figure 3b). Further, 1:1
diluted plasma (in PBS), showed about half of the inhibi-
tion level of the original plasma (data not shown). Inhibi-
tion of sporozoites by purified plasma IgG of protected
mice resulted in a similar inhibition level as non-purified
plasma (data not shown). Although the % inhibition
between individual plasma samples differs between mice,
the duplicates of one plasma sample diverged at most on
average 4% of the mean value of that sample (n = 21).
These results show that this adapted TSNA is a more user
friendly methodology, allowing identification of antibody-
mediated inhibition of parasite liver invasion.
Discussion
This study shows that PbGFP-Luccon parasites, can pro-
vide real-time quantitative information on the relation
between in vivo parasite liver load and immunity against
malaria. In vitro use of these parasites in the adapted
TSNA allows for an easy and fast assessment of the func-
tional sporozoite invasion inhibition by antibodies.
Previously, Mwakingwe et al. applied bioluminescent
imaging and qRT-PCR to analyse parasite prevalence in
the liver of immunized mice, using luciferase expressing
P. yoelii [5]. They did not, however, report on the direct
quantitative relation between bioluminescent imaging and
p a r a s i t e( l i v e r )l o a dd e t e r m i n e db yq R T - P C Ra n dt h e
extent to which the transgenic parasite had similar charac-
teristics as the WT parasite throughout the whole life
cycle [5]. In the future, a Py-Luc parasite that meets these
requisites for assessment of the liver load upon challenge,
can be used beside PbGFP-Luccon parasites, allowing for a
direct comparison of the characteristics of P. yoelii and P.
berghei in vivo.
Evaluation of immunity against malaria by biolumines-
cent imaging offers many advantages over conventional
qRT-PCR analysis. This analysis technique is more simple,
rapid and reduces the amount of mice needed. As an
added value, expression of the reporter protein luciferase
is restricted to live parasites and therefore allows specific
detection of live parasites. This avoids detection of dead
liver parasites, as may occur by the qRT-PCR assay [1].
Measurement of parasite liver load upon challenge can be
performed in vivo without the need for any invasive liver
resection or biopsy. It does not require sacrificing animals
and thereby reduces the number of animals and costs
required for experimentation. Moreover, multiple mea-
surements can be carried out in the same animal over
time, linking the parasite liver load with protection and
minimizing the effect of biological variation [6,7]. While
the use of PbGFP-Luccon over qRT-PCR has its clear bene-
fits, there are limitations. The expression of luciferase in
the parasite is relatively low and cannot be visualized ear-
lier than 20 hours post-infection [1]. Moreover, due to
limitations in sensitivity, a low number of developing liver
parasites may be missed which might mature into asexual
parasites [1]. Negative results of in vivo imaging of liver
stage development can therefore not be used to claim ster-
ile protection, which eventually requires sub-inoculation of
blood from challenged mice into naive mice [3]. Nonethe-
less, challenge of mice with a high number of PbGFP-Luc-
con sporozoites administered i.v does offer information on
the parasite liver load in real time without sacrifying the
mice. In the CPS model the overwhelming majority of the
parasites do not develop in the liver beyond 30 hours. The
presence of effector mechanisms that target early develop-
ing parasite stages can however, not formally be excluded.
At least in this model with complete liver stage develop-
ment, a high degree of immunity to late liver stage para-
sites can clearly be inferred.
Finally, the application of PbGFP-Luccon parasites is not
restricted to the described assays. In a recent publication
describing the host mediated factors regulating the inhibi-
tion of liver stage infection upon superinfection, luciferase
expressing parasites were used to enable distinction
between the parasites from the original infection and the
superinfection [8].
Conclusions
With clear benefits over conventional RT-qPCR techni-
ques, PbGFP-Luccon parasites can function as an easy and
valuable tool contributing to the comprehension of the
immunological principles underlying immunity against
malaria. As such, these parasites can be helpful in future
studies evaluating protection against malaria.
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Figure 3 Transgenic PbGFP-Luccon sporozoite hepatocyte invasion inhibition assay. (A) Huh-7 cells were seeded in 24 well plates and were
grown to confluency as described in Materials and Methods. Graded numbers of PbGFP-Luccon sporozoites were added to the culture wells in
duplicate and incubated for 40 h at 37 C in 5% CO2. Infectivity was quantified by analyzing the luminescent flux (p/sec/cm
2) in each well. (B)
Invasion inhibition of sporozoites by plasma from CPS (n = 6) and RAS (n = 7) immunized mice. 30.000 PbGFP-Luccon sporozoites were
incubated in plasma of naive or immune mice for 30 min on ice and subsequently added to Huh-7 cells. Infectivity was quantified by analyzing
the luminescent flux (p/sec/cm
2) in each well. The baseline represents the inhibition level of plasma from naive mice (approximately 4 × 10^7
p/sec/cm
2). Percent inhibition was calculated by the following formula; 1 - (average bioluminescence in immune plasma sample/average
bioluminescence in naive plasma sample) × 100%. The level of invasion inhibition in the immunized mice was significantly higher compared to
the inhibition from the plasma of naive mice (95% CI CPS 36-79%; 95% CI RAS 58-81%).
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Page 6 of 7List of abbreviations
PbGFP-Luccon: Plasmodium berghei that constitutively express firefly
Luciferase and the Green fluorescent protein; PbCS(pf): Plasmodium berghei
that bears the Plasmodium falciparum CS repeats; TSNA: Transgenic
sporozoite neutralization assay; RAS: Radiation attenuated sporozoites; CPS:
Sporozoites under chloroquine prophylaxis; ROI: Region of interest; q-RTPCR:
quantitative real-time polymerase chain reaction; IVIS: in vivo imaging
system.
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